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Identifying unaffected women with a BRCA mutation can have a significant individual and 
population health impact on morbidity and mortality if these women adhere to guidelines for 
managing cancer risk. But, little is known about whether such women are adherent to current 
guidelines. We conducted telephone surveys of 97 unaffected BRCA mutation carriers who had 
genetic counseling at least one year prior to the survey to assess adherence to current guidelines, 
factors associated with adherence, and common reasons for performing and not performing 
recommended risk management. More than half of participants reported being adherent with 
current risk management recommendations for breast cancer (69%, n=67), ovarian cancer (82%, 
n=74) and both cancers (66%, n=64). Older age (OR=10.53, p=0.001), white race (OR=8.93, 
p=0.019), higher breast cancer genetics knowledge (OR=1.67, p=0.030), higher cancer-specific 
distress (OR=1.07, p=0.002) and higher physical functioning (OR=1.09, p=0.009) were 
significantly associated with adherence to recommended risk management for both cancers. 
Responses to open-ended questions about reasons for performing and not performing risk 
management behaviors indicated that participants recognized the clinical utility of these behaviors. 
Younger individuals and those with lower physical functioning may require targeted interventions 
to improve adherence, perhaps in the setting of long-term follow-up at a multi-disciplinary 
hereditary cancer clinic.
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INTRODUCTION
Hereditary Breast and Ovarian Cancer (HBOC) syndrome, caused by inherited mutations in 
BRCA1 and BRCA2 genes, poses a substantial health burden on an individual and 
population basis, with significantly increased lifetime risks of breast and ovarian cancer 
(Chen & Parmigiani, 2007) and an estimated population prevalence of 1:400 (Petrucelli, 
Daly, & Feldman, 2013). Yet, this health burden can be greatly mitigated through 
prophylactic surgery and surveillance, which are associated with significant reduction in 
morbidity and mortality among women with HBOC syndrome (A. Finch et al., 2006; A. P. 
Finch et al., 2014; Kurian, Sigal, & Plevritis, 2010; Rebbeck et al., 2004; Rebbeck, Kauff, & 
Domchek, 2009; Warner et al., 2011).
Therefore, the Centers for Disease Control and Prevention’s Office of Public Health 
Genomics ranks HBOC syndrome as having top-tier evidence (Khoury, Coates, & Evans, 
2010) for integrating genomic information into public health practice for reducing morbidity 
and mortality (CDC, 2014). Since 2000, the National Comprehensive Cancer Network 
(NCCN) expert consensus guidelines have specified the timing and frequency of 
prophylactic surgery and surveillance for individuals with HBOC syndrome (NCCN, 2015). 
There are compelling public health and clinical reasons for determining whether those with 
HBOC syndrome are adherent to these guidelines. As Schwartz et al. (2003) argue, “[f]or 
BRCA1/2 testing to reach its potential to reduce cancer mortality and morbidity, receipt of a 
positive test result must be followed by the adoption of appropriate prevention or 
surveillance behaviors” (Schwartz et al., 2003).
Buchanan et al. Page 2
J Genet Couns. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Standard-of-care cancer genetic counseling, which includes pre- and post-test discussion of 
risk management options, should include encouragement for adoption of recommended 
behaviors (American Society of Clinical Oncology, 2003; Berliner, Fay, & Practice Issues 
Subcommittee of the National Society of Genetic Counselors’ Familial Cancer Risk 
Counseling Special Interest, 2007; Robson et al., 2009; Trepanier et al., 2004). Prevention 
and early detection may have the biggest impact on morbidity and mortality for unaffected 
mutation carriers (i.e., those without cancer), but we know little about risk management 
among this at-risk group.
Available data suggest wide variation in uptake of prophylactic surgery, with rates ranging 
from 18% to 74% (Bradbury et al., 2008; Garcia et al., 2014; H. Meijers-Heijboer et al., 
2003; Metcalfe et al., 2008; Schmeler et al., 2006; Sidon et al., 2012), and sub-optimal rates 
of breast and ovarian cancer surveillance (Botkin et al., 2003; Garcia et al., 2014; Kinney et 
al., 2006; Lerman et al., 2000; Metcalfe et al., 2008; Peshkin et al., 2002; Phillips et al., 
2006; Tinley et al., 2004; Uyei et al., 2006). Yet, this literature is often limited by short 
follow-up time (Claes et al., 2005; Kinney et al., 2006; Lerman et al., 2000; Lodder et al., 
2002; Peshkin et al., 2002; Schwartz et al., 2003), small sample size (Botkin et al., 2003; 
Bradbury et al., 2008; Claes et al., 2005; Kinney et al., 2006; Peshkin et al., 2002; Tinley et 
al., 2004; Uyei et al., 2006), highly selected samples with access to no-cost genetic 
counseling and risk management (Botkin et al., 2003; Bradbury et al., 2008; Claes et al., 
2005; Lerman et al., 2000; E. J. Meijers-Heijboer et al., 2000; Peshkin et al., 2002), and 
mixed samples of affected and unaffected mutation carriers (Scheuer et al., 2002).
Another limitation of previous research is that current adherence has not been assessed 
(Botkin et al., 2003; Garcia et al., 2014). Reports typically focus on whether a behavior has 
ever been performed rather than whether it has been performed within the recommended 
time period (Metcalfe et al., 2008). Assessing adherence to current risk management 
recommendations is important because risk management guidelines for carriers have evolved 
as new evidence has emerged to support the effectiveness of surveillance and prophylactic 
surgery (Burke et al., 1997; NCCN, 2015). Hence, it is possible that carriers who would have 
been considered adherent years ago are no longer adherent. Indeed, they may not even be 
aware of current guidelines.
We conducted telephone interviews among 97 unaffected BRCA mutation carriers to address 
three research questions: 1) To what extent are unaffected BRCA mutation carriers adherent 
to current NCCN risk management guidelines? 2) Which participant characteristics and 
beliefs are associated with adherence and non-adherence to these guidelines? and 3) What 
are common reasons for performing and not performing recommended breast and ovarian 
cancer risk management?
Knowing why unaffected carriers are or are not adherent to recommended risk management 
can facilitate development of interventions to improve adherence and therefore achieve the 
public health benefits of identifying BRCA mutation carriers.
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METHODS
Design
We used a cross-sectional, single-group design to assess adherence to current risk 
management recommendations and reasons for adherence and non-adherence among 
BRCA1/2 mutation carriers who had not been diagnosed with breast or ovarian cancer at the 
time of the interview. The study was approved by institutional review boards of Duke 
University Medical Center and The University of North Carolina – Chapel Hill.
Theoretical Framework
The Health Belief Model (HBM) (C.S. Skinner, Tiro, & Champion, 2015) and literature 
review informed selection of variables measured via the survey. As shown in Figure 1, the 
HBM can be readily applied to determining which factors are associated with prophylactic 
surgery or surveillance in unaffected mutation carriers. Modifying factors such as age, 
cancer worry and knowledge can influence beliefs about cancer and performance of risk 
management (e.g., perceived cancer risk, perceived self-efficacy to perform behaviors). The 
HBM posits that these beliefs and relevant cues to action (e.g., physician recommendation) 
affect likelihood of adherence. Although HBM variables have been associated with risk 
management behaviors (Bradbury et al., 2008; Claes et al., 2005; Hughes et al., 2002; 
Lerman et al., 2000; Schwartz et al., 2003; Tinley et al., 2004; Uyei et al., 2006), no previous 
studies have assessed all of these variables. Nor have previous studies been designed to 
suggest variables to target in an intervention.
Sample
Eligible women were BRCA mutation carriers age 25 or older, with no personal history of 
breast or ovarian cancer, who had standard-of-care pre- and post-test cancer genetic 
counseling at Duke Cancer Institute or The University of North Carolina’s Cancer Center. 
These clinics have been active since 1996. Age 25 was the lower age limit of eligibility 
because NCCN guidelines recommend that BRCA carriers begin imaging for breast cancer 
surveillance at this age (NCCN, 2015). BRCA carriers who had breast or ovarian cancer 
were excluded because their risk management is individualized according to a variety of 
clinical factors beyond the scope of the study to assess. Carriers who received results less 
than one year ago were excluded because they may not have had sufficient time to engage in 
recommended risk management behaviors. There was no upper limit for eligibility on time 
since results disclosure.
Genetic Counseling
At the Duke and UNC clinics, pre-testing genetic counseling is conducted in-person, with 
patients in select remote clinics affiliated with Duke and UNC having the option for a 
telemedicine visit via live videoconferencing beginning in 2008. Patients are given the 
choice to discuss genetic test results in person or via phone. Patients with positive or 
uncharacterized variant results who elect to discuss results via phone are encouraged to 
return in person (or via telemedicine) for a more detailed discussion of the results. 
implications. Results sessions for individuals with mutations include a discussion of the 
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NCCN-recommended risk management behaviors (NCCN, 2015). Genetic counselors at 
each clinic coordinate short-term follow-up (e.g., referrals to high-risk breast clinic or 
psychosocial counseling) for patients with a mutation as needed. As is standard of care 
(Riley et al., 2012), neither clinic performs ongoing coordination of risk management.
Recruitment and Data Collection Procedures
A genetic counselor at each clinic queried clinic databases for a list of patients who met 
eligibility criteria and mailed these patients a letter, signed by the clinic director, describing 
the study and giving a toll-free number to call to opt out of further contact. Three weeks 
after mailing the letter, Duke and UNC staff members securely uploaded to REDCap™ 
(Harris et al., 2009) the names and contact information of those patients who had not opted 
out. Study staff then attempted to contact these individuals to describe the study and 
administer the survey to those who gave verbal consent to participate. Computer-assisted 
telephone interviewing, in which staff entered survey responses electronically in real time, 
produced survey data with low item non-response and high detail on open-ended questions. 
Recruitment calls continued until the interviewer exhausted the list of potentially eligible 
patients. Study recruitment period was July 2012–February 2013.
After completion of all surveys, a nurse practitioner with experience in cancer genetics, but 
no involvement with either clinic, audited clinic charts to determine which risk management 
behaviors were discussed by the genetics team during results disclosure session. For each 
behavior, the auditor determined whether the recommendation recorded in the chart was to 
“recommend,” “consider,” or “do not have” the procedure; additional options included 
“recommendation unclear, “not mentioned,” and, for mastectomy/oophorectomy, “not 
applicable” due to already having already undergone the procedure. The recommended 
frequency for mammography was also recorded from the chart. A genetic counselor at each 
clinic queried the clinical databases for additional variables.
Measures
Prior to survey administration, we pre-tested the survey via cognitive interviewing (Willis, 
2005) with 16 female, affected BRCA mutation carriers in two iterative rounds of testing to 
ensure item and response option comprehension and ability to recall information. The final 
telephone survey assessed performance of each risk management behavior within the 
recommended time frame. Time since last mammogram and breast MRI were assessed with 
measures adapted from our previous work (C. Skinner et al., 2005). To determine whether 
participants had considered ovarian cancer surveillance, we asked whether they had decided 
to have surveillance, decided not to have surveillance, thought about surveillance but haven’t 
decided, or haven’t thought much about surveillance. Performance of risk management 
behaviors was assessed via self-report rather than medical records review because of 
acceptable validity for similar screening behaviors (Caplan et al., 2003; King, Rimer, Trock, 
Balshem, & Engstrom, 1990; Zapka et al., 1996), and because many of the patients who had 
genetic counseling and testing in the participating clinics receive ongoing care elsewhere. 
Open-ended items developed for this study assessed reasons to do and not do a behavior: 
“What do you see as the main reasons TO [perform risk management behavior]?” and “What 
do you see as the main reasons NOT to [perform risk management behavior]?” We were 
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interested in how participants viewed the risk management behaviors in general, rather than 
in their personal perceived benefits and barriers, because we thought it would provide a 
more comprehensive picture of the positive and negative messages they have received on 
each risk management behavior.
The survey also measured several HBM-based modifying factors, individual beliefs and cues 
to action that have been associated with risk management behaviors in previous studies 
(Bradbury et al., 2008; Claes et al., 2005; Lerman et al., 2000; Peshkin et al., 2002; 
Schmeler et al., 2006; Schwartz et al., 2003; Tinley et al., 2004; Uyei et al., 2006). Patients. 
report of recommended risk management (i.e., what behaviors were recommended and how 
often were they recommended, if applicable) was assessed using items from Tinley et al. 
(Tinley et al., 2004). Perceived breast and ovarian cancer risk were assessed by a single item 
that uses a 5-point scale to ask women whether they perceive their breast/ovarian cancer risk 
to be much lower, lower, the same, higher or mugh higher than other women their age 
(Schwartz et al., 2003). Breast and ovarian cancer worry were each assessed via a three-item 
measure that asks women how often in the last month they have thought about their chances 
of developing breast/ovarian cancer and how often these thoughts have affected their daily 
activities (4-point scale: not at all, sometimes, often, or a lot) (Schwartz et al., 2003). 
Anxiety and cancer-specific distress were measured via the state subscale of the State-Trait 
Anxiety Inventory (STAI) (Spielberger, Gorsuch, Lushene, & al., 1983) and Impact of 
Events Scale (IES) (Horowitz, Wilner, & Alvarez, 1979), respectively (4-point scale: not at 
all, somewhat, moderately so, very much so; and 4-point scale: not at all, rarely, sometimes, 
often, respectively). Knowledge of breast cancer genetics was measured using a 10-item 
true-false scale tested by Calzone et al. (Calzone et al., 2005). Physical and mental 
functioning were assessed via the Short-Form (SF-12) Health Survey (Ware, Kosinski, & 
Keller, 1996), which asks participants to rate their physical and mental health and the degree 
to which their health limits daily physical and social activities. Participants are described 
hereafter according to whether they scored higher or lower in perceived physical and mental 
functioning (e.g., lower physical functioning). Communication of results with family 
members was assessed via a scale developed by Patenaude et al., which asks women to state 
the number of first- and second-degree relatives who were living at the time of results 
disclosure and report with which of these relatives they discussed their BRCA results 
(Patenaude et al., 2006). Demographics and number of relatives with breast or ovarian 
cancer were assessed with items from our previous work (Buchanan et al., 2009; C. Skinner 
et al., 2005; C. S. Skinner et al., 2011).
Participants were asked to recall what their genetics team had recommended for each risk 
management behavior. First, participants were asked whether their genetics team had 
discussed the behavior. Those who answered „yes. were asked to select what the genetics 
team recommended for the behavior using a close-ended item (e.g., “How often did your 
genetic counselor or geneticist recommended that you have a breast MRI: every 6 months; 
every year; every 2 years; another interval of time:____; he or she didn’t say; he or she 
recommended that you NOT have a breast MRI; don’t remember”.) They were also asked to 
recall risk management recommendations made by other clinicians at any time post results 
discussion, and were asked via a close-ended item what the recommending clinicians. 
specialties were (e.g., primary care doctor, gynecologist, oncologist, surgeon). To account 
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for participants receiving different recommendations from multiple clinicians, participants 
were allowed to select multiple management recommendations and clinician specialties for 
each behavior.
Other variables that could be associated with adherence (age, time from receipt of test 
results to survey completion, gene with pathogenic variant – BRCA1 or BRCA2) (Bradbury 
et al., 2008; Lerman et al., 2000; Peshkin et al., 2002; Scheuer et al., 2002; Schmeler et al., 
2006; Schwartz et al., 2004; Uyei et al., 2006) were assessed by querying our clinical 
databases.
Variables and Statistical Analysis
Adherence to recommended risk management, a dichotomous variable, was calculated 
separately for each cancer according to 2012 NCCN guidelines, the most recent guidelines 
at the time of data collection and analysis. Participants were considered to be adherent to 
breast cancer risk management recommendations if they have had: (a) bilateral mastectomy 
ever OR (b) mammogram and breast MRI within the last 15 months. NCCN guidelines 
recommended that women with a BRCA mutation consider ovarian cancer surveillance via 
CA-125 testing and pelvic ultrasounds, rather than recommending that women perform 
surveillance (NCCN, 2012). Therefore, participants were considered adherent to ovarian 
cancer risk management recommendations if they have had: (a) bilateral salpingo-
oophorectomy ever OR (b) had ever considered CA-125 testing and pelvic ultrasound. We 
included participants as having considered ovarian cancer surveillance if they responded that 
they had decided to have it, decided not to have it or thought about it but had not decided. 
We calculated the proportions of participants who met these criteria and the exact 95% 
binomial confidence interval for these estimates.
We calculated descriptive statistics for demographic factors (e.g., age, race/ethnicity, 
education, insurance status), cancer family history, and calculated scores for cancer genetics 
knowledge, perceived cancer risk, and cancer-related worry, anxiety and distress. 
Participants. recall of breast and ovarian cancer risk management recommendations made by 
their genetics team at results disclosure and by their physician(s) at any point after disclosure 
was compared with 2012 NCCN recommendations. For each cancer type, and for genetics 
team recommendations and physician recommendations, we developed dichotomous 
variables of concordance between recalled recommendations and NCCN recommendations 
(all/some recalled recommendations concordant vs. no recommendations concordant). All or 
some were combined to reduce the chances of small cell sizes for the bivariate models. We 
developed similar, dichotomous variables to summarize concordance between medical 
records-abstracted recommendations made by the genetics team at results disclosure and 
current NCCN recommendations. Bivariate and multivariable logistic regression models 
were used to assess associations between participant characteristics and adherence to risk 
management guidelines separately for breast cancer, ovarian cancer, and adherence for both 
cancers. For each adherence outcome, the final multivariable model was selected using 
backwards stepwise selection, starting with a model that included all variables significant at 
p < 0.1 in bivariate analysis. We used p-value threshold higher than 0.05 for entry into the 
multivariable model to reduce the chance of excluding a potentially significant variable from 
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the final model. We then removed non-significant variables one-at-a-time until only 
variables significant at p < 0.05 remained. R2 values (calculated using the Cox & Snell 
method) and likelihood p-values comparing final and null models were calculated for the 
final multivariable models.
Data from the open-ended items were content-analyzed to identify common reasons for 
adherence and non-adherence. We used manifest content analysis (Hsieh & Shannon, 2005), 
which is appropriate when relatively little is known about a phenomenon and the goal is to 
generate descriptive data for hypothesis generation. Two study investigators (AB and CV) 
coded the reported reasons for adherence and non-adherence together. Any initial 
disagreements in coding were resolved through discussion during the coding process. For 
each reason identified, we calculated a manifest frequency effect size (i.e., proportion of 
participants who listed that reason) (Onwuegbuzie, 2003). Reasons for adherence and non-
adherence were ranked separately to elucidate prominent facilitators of and barriers to 
adherence, which then can be targeted in future interventions.
RESULTS
Enrollment Summary
As summarized in Figure 2, queries of clinic databases identified 178 potentially eligible 
individuals. Study staff were unable to reach 56 of these individuals by phone. Of those who 
were reached, six were found to be ineligible due to diagnosis of breast or ovarian cancer 
since results disclosure and twelve declined participation. Women who completed the survey 
were similar to those who did not complete the survey with respect to age, race and Hispanic 
ethnicity (p > 0.5 for all three comparisons). However, women seen at Duke agreed to 
participate at a greater rate than those seen at UNC (63% vs 47%, p=0.04).
Participant Characteristics
Participant characteristics, shown in Table I, did not differ significantly by clinic. 
Participants were largely Caucasian, married, employed, well-educated, well insured and 
had income higher than $50,000. The majority of participants who were not Caucasian were 
African American. Median number of years since results disclosure was 3.7 among Duke 
participants and 4.5 among UNC participants. Median breast cancer genetics knowledge 
score was high (9 out of 10 in both clinics). Cancer-specific distress was 7.0 among Duke 
participants and 12.0 among UNC participants (scale range 0–75 – see Table 1). On average, 
participants reported communicating test results with 75% of their living first- and second-
degree relatives.
Nearly one third of participants (31%) reported receiving conflicting risk management 
recommendations from different physicians after they received their genetic test results. 
Eighty percent of participants reported that their genetics team recommended breast cancer 
risk management that was concordant with some or all of the corresponding 2012 NCCN 
recommendations; 38% of participants reported that their genetics team made ovarian cancer 
risk management recommendations that were consistent with 2012 NCCN 
recommendations. Participants reported similar concordance between post-disclosure 
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physician recommendations for breast and ovarian cancer risk management and the 
corresponding 2012 NCCN recommendations, with 76% concordance for some or all breast 
cancer risk management recommendations and 24% concordance for some or all ovarian 
cancer risk management recommendations. By medical records review, genetics team 
recommendations for breast cancer risk management were concordant with some or all of 
the corresponding 2012 NCCN recommendations for 88% of participants. Genetics team 
recommendations for ovarian cancer risk management were concordant with some or all of 
the corresponding 2012 NCCN recommendations for 1% of participants.
Adherence to Recommended Risk Management
More than half of participants were adherent with risk management recommendations for 
breast cancer, ovarian cancer and both cancers (Table II). Adherence was highest among 
participants age 40 years and older, with rates of 75% or greater. Among participants 
adherent to recommended breast cancer risk management, 51% had bilateral mastectomies 
and 49% had both surveillance tests within the recommended time period. Among those 
adherent to recommended ovarian cancer risk management, 72% had bilateral 
oophorectomies and 28% had considered both surveillance tests.
Factors Associated with Adherence
In bivariate analyses that included all participant characteristics in Table I, white race, higher 
income, higher breast cancer genetics knowledge, and higher physical functioning were 
associated with greater adherence to breast cancer risk management (Table III). In 
multivariable analyses, white race (OR=4.80, 95% CI=1.21–19.06, p=0.026) and higher 
knowledge (OR=1.61, 95% CI=1.10–2.34, p=0.013) remained significantly associated with 
adherence (R2 = 0.12, p=0.0022).
Older age, higher income and higher physical functioning were associated with greater 
adherence to recommended ovarian cancer risk management in bivariate analyses (Table III). 
Older age (OR=7.25, 95% CI=1.36–38.46, p=0.020 for age 40+ v. 30–39) and higher 
household income (OR=8.49, 95% CI=1.62–43.86, p=0.011) remained significantly 
associated with adherence in the multivariable model (R2 = 0.13, p=0.0029).
In bivariate analyses, older age, white race, higher income, higher breast cancer genetics 
knowledge, higher cancer-specific distress, higher physical functioning, and greater 
concordance between current NCCN guidelines and participants. report of physicians. 
ovarian cancer risk management recommendations were associated with greater adherence 
to risk management for both cancers (Table III). Older age (OR=4.76, 95% CI=1.02–22.22, 
p=0.047 for age 40+ v. 25–29; OR=10.53, 95% CI=2.56–43.48, p=0.001 for age 40+ v. 30–
39), white race (OR=8.93, 95% CI=1.43–55.56, p=0.019), higher knowledge (OR=1.67, 
95% CI=1.05–2.65, p=0.030), higher cancer-specific distress (OR=1.07, 95% CI=1.03–1.12, 
p=0.002) and higher physical functioning (OR=1.09, 95% CI=1.02–1.15, p=0.009) remained 
significantly associated with adherence to recommended risk management for both cancers 
on multivariable analyses (R2 = 0.32, p<0.0001).
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Reasons to Perform and Not Perform Recommended Behaviors
The most commonly reported main reasons to have and not to have each risk management 
behavior are summarized in Tables IV and V. Because responses for prophylactic surgery 
tended to differ from those for surveillance, surgery and surveillance tables are presented 
separately. Participants reported risk reduction as the most common reason to perform 
prophylactic surgery (Table IV). The ability of surveillance tests to detect abnormalities and 
to do so early were the most commonly reported reasons to have surveillance (Table V). 
Some participants reported nuanced views of surveillance, including a recognition that 
breast MRI can be more sensitive that mammography but may be costly, and that there are 
clinical validity concerns with ovarian cancer surveillance (Table V). Of note, substantial 
proportions of participants (ranging from 10% for prophylactic oophorectomy to 59% for 
mammography) were unable to think of reasons not to perform prophylactic surgery and 
surveillance (Tables IV and V). The list of reasons not to have prophylactic surgery was 
short and, for prophylactic oophorectomy, was focused on wanting to maintain fertility and 
avoid menopausal symptoms (Table IV).
DISCUSSION
We found that adherence to 2012 NCCN guidelines for cancer risk management among 
unaffected female BRCA mutation carriers who underwent standard-of-care cancer genetic 
counseling at one of two NCI-designated comprehensive cancer centers exceeded 50%, with 
adherence rates greater than 75% in women older than age 40. Rates of prophylactic surgery 
reported in our study (prophylactic oophorectomy=63%, prophylactic mastectomy=35%) 
were consistent with rates in several similar studies (Bradbury et al., 2008; Friebel et al., 
2007; Garcia et al., 2014; Schwartz et al., 2012). Our qualitative findings suggest that 
participants recognized prophylactic surgery and surveillance as effective methods for 
managing one’s risk for breast and ovarian cancer. Several were unable to think of reasons 
not to perform risk management behaviors. Given that median time since test results 
disclosure was 3.7 years in the Duke clinic participants and 4.5 years in the UNC clinic 
participants, the relatively high self-reported adherence to all recommended management is 
encouraging, though it does leave room for improvement – and possible targets for 
interventions – among women under 40 and other sub-groups.
Several factors were significantly associated with adherence to recommended risk 
management for breast cancer, ovarian cancer and both cancers. Some of these findings can 
be readily applied to development of interventions to improve adherence, while others 
require further study or are less amenable to intervention. Consistent with several other 
reports of factors associated with risk-reducing surgery (Botkin et al., 2003; Bradbury et al., 
2008; Friebel et al., 2007; Garcia et al., 2014; Julian-Reynier et al., 2010; O’Neill et al., 
2010; Schmeler et al., 2006; Schwartz et al., 2012), older age was associated with greater 
adherence to recommended management for ovarian cancer and for both cancers together. 
Maintaining fertility and the ability to breastfeed were the most commonly reported reasons 
to not have prophylactic surgery. This finding echoes recent qualitative studies of risk 
management among unaffected women with HBOC syndrome, which have described the 
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complex decision making involved in balancing fertility and breastfeeding with risk 
management (Caiata-Zufferey & Pagani, 2015; Leonarczyk & Mawn, 2015).
Higher breast cancer genetics knowledge was significantly associated with higher adherence 
to breast cancer risk management and to recommended management for both cancers. This 
suggests that a basic level of genetic literacy, specific to a condition, may be associated with 
greater adherence to recommended management for that condition. Perhaps the high 
knowledge in both clinic populations and association between knowledge and adherence are 
indications of effective genetic counseling, as others have found (Calzone et al., 2005; 
Hadley et al., 2004; Pal et al., 2014; Scheuer et al., 2002; Watson et al., 2005). Or, perhaps 
this particular population was already knowledgeable about HBOC genetics and risk 
management. A majority of participants (77%) had single-site genetic testing, indicating that 
their families were already aware of a familial BRCA mutation. If family communication 
about the mutation included basic genetics and risk management concepts, this 
communication could have been responsible for the high knowledge and adherence. Studies 
to determine the type and amount of information associated with adherence and mode for 
delivering this information (e.g., standard cancer genetic counseling, primary care physician 
discussion, family communication) are warranted.
Our finding that higher physical functioning was associated with greater adherence to 
recommended risk management for both cancers is intuitive, as poorer functioning makes it 
difficult to perform surveillance or undergo prophylactic surgery. Although we found that 
cancer-specific distress was associated with adherence to risk management for both cancers, 
it is notable that distress was in the intermediate range (median=12) among those adherent 
for both cancers, whereas distress for those non-adherent for both cancers was in the low 
range (median=4.5). This may be another example of the Yerkes-Dodson law (Yerkes & 
Dodson, 1908), in which there is a “just right” amount of distress that spurs action but is not 
debilitating.
Practice Implications
Standard-of-care cancer genetic counseling is designed to facilitate some of the factors we 
found to be associated with adherence, including educating about the basic genetics of a 
hereditary cancer syndrome and improving risk perception while providing patients with 
achievable methods of managing their risks (American Society of Clinical Oncology, 2003; 
Berliner, Fay, Cummings, Burnett, & Tillmanns, 2013; Berliner et al., 2007; Trepanier et al., 
2004). What interventions might we suggest, then, that go beyond standard cancer genetic 
counseling to further support women who remain non-adherent?
Enlisting supportive resources (e.g., clinic social worker, online support groups) may help 
younger women who are not prepared to proceed with prophylactic surgery to remain 
adherent to surveillance recommendations. These supportive resources may need to be 
available long-term, given that decisions about risk management can remain complex as 
women pass through different life stages, creating what some women with HBOC syndrome 
have described as a “lifelong risk balance analysis” (Leonarczyk & Mawn, 2015). Providing 
logistical support for those with poorer physical functioning may include collaborating with 
patient navigators, transportation to clinics for surveillance or better access to home health 
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nursing post-prophylactic surgery. Finally, any intervention tailored to an individual’s 
perceived barriers to adherence will need to be prepared to respond to a long list of barriers, 
as many of the reasons to not perform particular risk management behaviors were only 
mentioned by a few participants.
A longitudinal, multi-disciplinary hereditary cancer clinic could be the ideal setting for 
designing these informational, supportive and logistical interventions, and testing whether 
they improve adherence. Providing a single clinic at which women with HBOC syndrome 
could receive current, consistent information on risk management as guidelines change 
could mitigate disorientation reported by women who receive different recommendations 
from different clinicians (Caiata-Zufferey & Pagani, 2015; Leonarczyk & Mawn, 2015).
Research Recommendations
Among our findings that bear further study was the link between race and adherence to 
recommended risk management for breast cancer and for both cancers. It would be 
premature to draw major conclusions from our study given that there were only 11 minority 
participants. It is unlikely that race was a proxy for differential access to care in our study 
(Chagpar, Polk, & McMasters, 2008; Miranda, Tarraf, & Gonzalez, 2011) because nearly all 
participants (89%) were insured and, by virtue of having had cancer genetic counseling, 
were already connected to a cancer center that could provide their risk management.
The association between higher income and adherence to ovarian cancer risk management is 
an apparently novel finding that merits further study. The majority of women who were 
adherent for ovarian cancer risk management did so by having prophylactic oophorectomy. 
Perhaps having higher income makes it easier to manage post-surgery challenges such as 
recovery time and menopausal symptoms.
Our study was notable for what we did not find. Our Health Belief Model-based theoretical 
framework and previous research suggested a list of variables that could be associated with 
adherence, but were not. These included insurance status, education, cancer worry, family 
history of breast or ovarian cancer (Bradbury et al., 2008; Friebel et al., 2007; Julian-Reynier 
et al., 2010), mental functioning and the concordance of patient recall of geneticist-
recommended management with current management guidelines. Neither was time since 
results disclosure associated with adherence, which is surprising given that management 
guidelines have changed for at least one behavior in eight of the 15 years since risk 
management guidelines were first published in 1997 and the 2012 NCCN guidelines used 
for this study (Burke et al., 1997; NCCN, 2000, 2001, 2002, 2003, 2005, 2006, 2010, 2012). 
Surprising, too, was the finding that a substantial proportion of participants reported 
receiving conflicting risk management recommendations from different clinicians, but 
concordance between participants. recall of recommended behaviors and NCCN guidelines 
was not associated with adherence. Perhaps the lack of association between some of these 
characteristics and adherence is merely due to insufficient power. Larger studies of 
adherence may still include these characteristics.
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Study Limitations and Strengths
It is unclear how generalizable study findings are to community clinic settings or other 
regions. Data were drawn from two tertiary care institutions in close proximity to one 
another, with a significantly higher participation rate in the Duke clinic. And, although 
participants and non-participants did not differ significantly on age, race or Hispanic 
ethnicity, it is possible that they differed on factors that were not available in the clinic 
databases.
Among other study limitations is that the study was not designed to evaluate associations 
between specific perceived benefits of and barriers to adherence among those who were non-
adherent. This is due in part to the decision to ask participants about perceived benefits and 
barriers generally, rather than about their own perceived benefits and barriers. Additionally, 
given the sample size and the fact that the list of perceived benefits and barriers for many of 
the behaviors was fairly long and individualized, it is unlikely that there would have been 
sufficient power to investigate these associations even if we had intended to. Future studies 
may wish to assess the link between perceived benefits and barriers and adherence to 
recommended risk management, as well as the association between the balance of an 
individual’s perceived benefits of and barriers to risk management behaviors and adherence 
to recommended behaviors (O’Neill et al., 2010). Further, participants. self-report of risk 
management behaviors may be inaccurate. However, we are encouraged by previous reports 
of the validity of mammography self-report (Caplan et al., 2003; King et al., 1990; Rauscher, 
Johnson, Cho, & Walk, 2008; Zapka et al., 1996) and the correlation of patient report of 
screening and physician recommendation via chart audit (Montano & Phillips, 1995).
This study also has several strengths. It supplements previous literature by focusing on 
adherence to all recommended risk management behaviors among unaffected women, 
assessing characteristics associated with adherence in this population, and reporting 
qualitative data that add nuance to these associations. Additional strengths include a 
relatively long follow-up period during which management guidelines changed several 
times, the assessment of a broad range of variables potentially associated with adherence 
(including participants. recall of clinicians. management recommendations) and a theoretical 
framework to inform selection of these variables.
Conclusions
This study is among the first to provide an important snapshot of adherence to current 
recommended risk management among unaffected women with a BRCA mutation. We 
found that, in spite of a median of several years since results disclosure, a majority of 
participants were adherent with current management guidelines for unaffected women with a 
BRCA mutation. Adherence was particularly high among women older than age 40. 
Younger individuals and those with lower physical functioning may require targeted 
interventions to improve adherence, perhaps in the setting of long-term follow-up at a multi-
disciplinary hereditary cancer clinic. To ensure that all individuals with HBOC syndrome 
have the opportunity to realize the associated beneficial health outcomes, we propose 
assessing risk management adherence in a larger, more racially and ethnically diverse 
sample.
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Figure 1. 
Theoretical Framework
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Figure 2. 
Flowchart of recruitment and analysis
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Table I
Participant characteristics by clinic
Characteristics Duke
n (%)
UNC
n (%)
Fisher’s Exact Statistic Chi-
square (p-value)
Age 0.93 (0.68)
 25–29 years 6 (12.0) 7 (14.9)
 30–39 years 16 (32.0) 11 (23.4)
 40+ years 28 (56.0) 29 (61.7)
Race 2.93 (0.11)
 Non-White 3 (6.0) 8 (17.0)
 White 47 (94.0) 39 (83.0)
Hispanic ethnicity 2 (4.0) 3 (6.4) 0.28 (0.67)
Married/living as married 41 (82.0) 36 (78.3) 0.21 (0.80)
Employed 37 (74.0) 30 (66.7) 0.61 (0.50)
Education level 0.42 (0.53)
 Less than college graduate 18 (36.0) 14 (29.8)
 College graduate 32 (64.0) 33 (70.2)
Insurance status 3.06 (0.11)
 No private insurance 3 (6.0) 8 (17.4)
 Private 47 (94.0) 38 (82.6)
Household income 0.70 (0.48)
 ≤$50,000 10 (20.8) 13 (28.3)
 $50,001 and above 38 (79.2) 33 (71.7)
Mutated gene 0.87 (0.42)
 BRCA1 24 (48.0) 27 (57.5)
 BRCA2 26 (52.0) 20 (42.6)
Continuous variables (scale range) Median (Range, SD) Median (Range, SD) Wilcoxon test p-value
Years since results disclosure 3.7 (1.0–13.4, 2.8) 4.5 (1.1–12.9, 2.7) 0.23
Knowledge (0–10) 9.0 (6.0–10.0, 1.0) 9.0 (5.0–10.0, 1.4) 0.051
Breast cancer worry (3–9) 4.0 (3.0–8.0, 1.6) 3.0 (3.0–9.0, 1.5) 0.40
Ovarian cancer worry (3–9) 3.0 (3.0–8.0, 1.3) 3.0 (3.0–9.0, 1.3) 0.25
Anxiety (20–80) 28.0 (20.0–68.0, 8.7) 27.0 (20.0–65.0, 10.7) 0.61
Cancer-specific distress (0–75) 7.0 (0.0–59.0, 16.1) 12.0 (0.0–47.0, 15.2) 0.39
Physical functioning (0–100) 55.2 (19.5–62.4, 7.3) 54.8 (19.7–66.0, 11.6) 0.62
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Characteristics Duke
n (%)
UNC
n (%)
Fisher’s Exact Statistic Chi-
square (p-value)
Social functioning (0–100) 54.6 (31.8–62.7, 6.7) 54.1 (27.9–62.4, 9.3) 0.42
# relatives with breast cancer 3.0 (0.0–12.0, 2.4) 4.0 (0.0–19.0, 3.7) 0.20
# relatives with ovarian cancer 1.0 (0.0–6.0, 1.5) 1.0 (0.0–11.0, 2.1) 0.68
Proportion of relatives with whom results shared (0–
100)
75.1 (27.3–100.0, 20.7) 79.2 (11.1–100.0, 20.2) 0.16
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Table II
Adherence to recommend risk management, by cancer type and overall
Adherent, n (%, 95% confidence interval for %)
25–29y* 30–39y 40+ y
Breast cancer risk management 7 (53.9, 25.0–80.8) 17 (63.0, 42.4–80.6) 43 (75.4, 62.4–85.9)
Ovarian cancer risk management N/A 21 (77.8, 57.7–91.4) 53 (93.0, 83.0–98.1)
Risk management - both cancers 7 (53.9, 25.0–80.8) 14 (51.9, 32.0–71.3) 43 (75.4, 62.2–85.9)
*Counted as adherent for both cancers if adherent with breast cancer risk management
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Table IV
Primary reasons to have and not to have prophylactic surgery mentioned by ≥10% of participants (n=97)
Mastectomy
n (%)
Oophorectomy
n (%)
Reasons TO have surgery
Reduce risk 54 (56%) 67 (69%)
Treatment 23 (24%) <10%
Peace of mind 18 (19%) <10%
Completed childbearing <10% 17 (18%)
Genetic risk 0 14 (14%)
No good screening test 0 14 (14%)
Reduce estrogen 0 11 (11%)
Symptom management <10% 10 (10%)
Reasons NOT to have surgery
No reason not to 20 (21%) 10 (10%)
Have not completed childbearing/breastfeeding 16 (16%) 52 (54%)
Surgical complexity/complications 11 (11%) 0
Might not get cancer 10 (10%) 0
Side effects of menopause 0 30 (31%)
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Table V
Primary reasons to and not to have surveillance mentioned by ≥10% of participants (n=63 for breast cancer 
surveillance; n=44 for ovarian cancer surveillance)
Mammogram
n (%)
Breast MRI
n (%)
CA-125 testing
n (%)
Pelvic ultrasound
n (%)
Reasons TO have surveillance
Early detection 30 (48%) 24 (38%) 16 (36%) 13 (30%)
Detect abnormality 27 (43%) 10 (16%) 17 (39%) 29 (66%)
Better than alternative procedure <10% 27 (43%) 0 0
Physician recommendation <10% 13 (21%) <10% <10%
Symptom follow-up <10% 9 (14%) <10% <10%
Two tests are better than one 0 7 (11%) <10% <10%
Reasons NOT to have surveillance
No reason not to 37 (59%) 26 (41%) 14 (32%) 21 (48%)
Radiation exposure 10 (16%) <10% 0 0
Age (too young or too old) 10 (16%) <10% <10% <10%
Alternative procedure available 9 (14%) <10% 0 <10%
Dense breasts 8 (13%) <10% 0 0
Cost <10% 20 (32%) 6 (14%) 10 (23%)
Insurance status <10% 7 (11%) <10% <10%
Clinical validity <10% <10% 14 (32%) <10%
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